Search the Newsreel

23,257 Shares in Corcept Therapeutics Incorporated $CORT Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP recently acquired a new position of 23,257 shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the second quarter, valued at approximately $2.022 million. Other institutional investors have also adjusted their holdings in CORT, with 93.61% of the stock owned by hedge …

Is Jacobs Solutions (J) Undervalued Following Its Utah Project Win And Mixed Earnings?

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of "Hold" by Brokerages

BioLife Solutions (NASDAQ:BLFS) has received an average "Hold" recommendation from brokerages, with the majority of analysts issuing a hold rating. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Despite positive institutional investor activity, insiders have sold a …

Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts

Emergent Biosolutions Inc. (NYSE:EBS) has received an average "Hold" rating from analysts, with an average 12-month price target of $10.00. The company recently reported better-than-expected quarterly EPS of $0.60 and revenue of $234.3 million, though it posted a negative net margin and analysts anticipate …

Empowered Funds LLC Buys 25,775 Shares of MACOM Technology Solutions Holdings, Inc. $MTSI

Empowered Funds LLC significantly increased its stake in MACOM Technology Solutions Holdings, Inc. (MTSI) by 282.5% in Q1 2026, acquiring an additional 25,775 shares, bringing its total to 34,898 shares valued at $7.75 million. This comes as institutional investors and hedge funds own a …

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

Broadridge Financial Solutions, Inc. $BR Shares Bought by Empowered Funds LLC

Empowered Funds LLC increased its stake in Broadridge Financial Solutions (NYSE:BR) by 29.9% in the first quarter, bringing its total holdings to 48,430 shares valued at approximately $7.9 million. This move is part of a broader trend of institutional investors and hedge funds owning …

Empowered Funds LLC Buys 228,275 Shares of Viavi Solutions Inc. $VIAV

Element Solutions Inc. $ESI Shares Acquired by Bank of America Corp DE

Bank of America Corp DE increased its stake in Element Solutions Inc. (NYSE:ESI) by 3.3% in the first quarter, acquiring an additional 28,531 shares to own a total of 881,493 shares. Element Solutions reported strong Q2 earnings, beating analyst estimates with an EPS of …

Bridgewater Advisors Inc. Takes $2.06 Million Position in Essential Utilities Inc. $WTRG

Bridgewater Advisors Inc. has acquired a new stake of 54,792 shares in Essential Utilities Inc. (NYSE:WTRG), valued at approximately $2.06 million, according to its latest SEC filing. Other institutional investors have also recently adjusted their holdings in the company. Essential Utilities recently reported earnings …

Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE

Bank of America Corp DE Sells 27,029 Shares of Kratos Defense & Security Solutions, Inc. $KTOS

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Atlas Energy Solutions Inc. (NYSE:AESI) Receives Consensus Recommendation of "Hold" from Analysts

Atlas Energy Solutions Inc. (NYSE:AESI) has received a consensus "Hold" rating from ten analysts, with an average 12-month price target of $18.13. Recent analyst adjustments have seen several price targets lowered, including Citigroup to $21, Stifel to $25, Barclays to $10, and RBC to …

How Investors May Respond To Motorola Solutions (MSI) New Bond Issues And Updated 2026 Outlook

Motorola Solutions recently completed two senior unsecured fixed-rate bond offerings totaling US$949.01 million, issuing notes due 2029 and 2036. This comes as the company reported strong second-quarter results and raised its full-year 2026 revenue guidance to approximately US$12.975 billion, highlighting a strategy of combining …

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Helix Energy Solutions Group (NYSE:HLX) Rating Lowered to "Hold" at Wall Street Zen

Wall Street Zen has downgraded Helix Energy Solutions Group (NYSE:HLX) from "Buy" to "Hold." This aligns with the broader analyst consensus, which also rates the stock as "Hold" with a target price of $14.00. Despite exceeding EPS expectations in its latest quarterly report, the …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold

Wall Street Zen has upgraded Avalo Therapeutics (NASDAQ:AVTX) from a "sell" to a "hold" rating, though the consensus among other analysts remains a "Moderate Buy" with an average price target of $45.10. The company reported a quarterly loss of $0.83 per share, missing estimates. …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded Atara Biotherapeutics (NASDAQ:ATRA) from "Sell" to "Hold," reflecting an average "Hold" consensus among analysts with an average price target of $9.50. Despite the upgrade, ATRA shares opened down 4.9% at $8.09, with the company reporting a quarterly loss of …

Does MACOM’s Q3 Profit Surge And Higher Guidance Reshape The Bull Case For MTSI?

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Should I buy Scribe Therapeutics Inc. (SCTX)

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

Financial Institutions Stock: Still A Cautious Buy With Improved Outlook (NASDAQ:FISI)

Price-Driven Insight from (ZVRA) for Rule-Based Strategy

This article provides a price-driven analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and an exceptional risk-reward short …

Arcutis (ARQT) Q2 2026 Earnings Call Transcript

₹524: That's What Analysts Think Awfis Space Solutions Limited (NSE:AWFIS) Is Worth After Its Latest Results

Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress

Nektar Therapeutics' stock fell 4% following its Q2 2026 earnings report, despite progress in its autoimmune pipeline, notably rezpegaldesleukin. The market reacted negatively to the company's substantial cash burn, with a quarterly net loss exceeding US$40 million and trailing 12-month losses widening. While the …

Will Rising Revenue But Mounting Losses and Steady Payouts Change Brookfield Wealth Solutions' (BNT) Narrative

Brookfield Wealth Solutions Ltd. (NYSE:BNT) Short Interest Update